factors predicting durable remission after ifn therapy discontinuation in mpn patients
Published 3 years ago • 411 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
3:49
factors influencing mpn progression
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
2:45
an insight into clinical risk factors for progression in mpns
-
1:32
factors contributing to the pathogenesis of icaht
-
1:26
current and emerging prognostic factors for mds/mpn
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
0:41
isct in bringing together the scientific community
-
3:40
master class in transplantation and hematology: highlights
-
1:41
transplant optimization strategies
-
2:42
factors to consider when using haplo-sct: donor selection criteria and source of stem cells
-
1:05
risk-factors for richter’s transformation
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
3:19
supportive care in al amyloidosis
-
1:10
the importance of incorporating patient-reported outcomes in clinical practice
-
2:07
high-sustained factor & non-factor replacement therapy: reducing treatment burden in hemophilia